Neumora Therapeutics, Inc.

By person

16 insiders · 76 transactions

16.8×

Paul L. Berns holds 16.8 times base salary in stock. $11.80M of shares against $700.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Paul L. Berns last reported holding, valued at $1.60, the price Common Stock was last bought or sold at on the open market here, on 21 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

ARCH Venture Partners X, LLC entity

10% owner

$56.00M (3)

—

+$56.00M

6,046,907

3.22%

$9.65M

—

Burow Kristina

Director

$36.43M (20)

—

+$36.43M

6,094,624

3.24%

$9.73M

—

AMGEN INC entity

10% owner

$30.00M (1)

—

+$30.00M

35,368,653

18.82%

$56.44M

—

ARCH Venture Partners XII, LLC entity

10% owner

$10.93M (19)

—

+$10.93M

6,046,907

3.22%

$9.65M

+246.6%

Pinto Joshua

President & CEO

—

$1.20M (6) scheduled

−$1.20M

209,950

0.1117%

$335.04K

−56.1%

Lenz Robert A.

Head of R&D

—

$1.09M (6) scheduled

−$1.09M

309,092

0.1645%

$493.25K

—

Aurora Daljit Singh

See Remarks

—

$1.04M (14) scheduled

−$1.04M

48,750

0.0259%

$77.80K

−78.7%

Fust Matthew K

Director

—

$370.96K (2) scheduled

−$370.96K

20,100

0.0107%

$32.08K

—

Gosebruch Henry O

President & CEO

$189.37K (1)

—

+$189.37K

477,345

0.2540%

$761.75K

+24.8%

BERNS PAUL L

See Remarks

—

$57.93K (2)

−$57.93K

7,395,185

3.94%

$11.80M

−3.3%

Milligan Michael Lee

See Remarks

—

$8.47K (2) scheduled

−$8.47K

21,034

0.0112%

$33.57K

+450.2%

Suh Carol Y.

Chief Operating Officer

—

374,674

0.1994%

$597.90K

+29.3%

FMR LLC entity

See Remark 1

—

88,289

0.0470%

$140.89K

—

Ho Maykin

Director

—

20,100

0.0107%

$32.08K

—

Piacquad David

Director

—

20,100

0.0107%

$32.08K

—

Halawa Alaa

Director

—

20,100

0.0107%

$32.08K

—

Neumora Therapeutics, Inc.

By person

Individual transactions

What was left out